1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Deadline was December 8, 2025 at 5:00pm. Page explicitly states the DRC is no longer accepting applications for the current cycle. Award period April 1, 2026 – March 31, 2027.
Diabetes Research Center Pilot and Feasibility Grant Program is a grant from the Perelman School of Medicine at the University of Pennsylvania that funds pilot and feasibility studies in diabetes, endocrine, and metabolic disorders research. The program supports new investigators, established investigators new to diabetes research, and experienced diabetes researchers pursuing high-impact or high-risk projects.
Eligible applicants must hold faculty appointments and be eligible to submit an NIH R01 as PI at the start of the grant period; basic, clinical, and translational researchers are all welcome. A second year of funding may be requested with demonstrated productivity. The application deadline for the 2026-2027 cycle was December 8, 2025.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Penn DRC Pilot and Feasibility Grant Program Overview DRC Pilot and Feasibility Grant Program Overview The Diabetes Research Center (DRC) of the University of Pennsylvania is no longer accepting applications for support to perform pilot and feasibility studies in diabetes and related endocrine and metabolic disorders for the 2026 - 2027 award cycle.
Application Deadline was Monday, December 8th, 2025, by 5:00 pm The P&F program is intended to support new investigators and established investigators new to diabetes research. Established diabetes investigators pursing high impact/high risk projects or projects that are a significant departure from their usual work are also eligible for support under the DRC P&F program.
Applications are welcome from basic, clinical and translational investigators. All eligible investigators must have faculty appointments at the commencement of the award and be independent investigators. The definition of faculty status may vary across institutions.
Therefore, eligibility to apply for this P&F grant is defined as being eligible to submit an R01 as a PI at the start of the grant period. Applications are welcomed from basic, clinical and translational investigators. A second year of funding is possible with demonstrated productivity.
Such continuation requests need to be carefully justified, however, and will be considered as a competing renewal application (see below). Support for a second year is not allowed if the applicant has received external funding for the same project. Pilot Grant eligibility is restricted to members of the Penn DRC and that investigators must be located at an Institution in the greater Philadelphia area.
Applicants must be US. citizens or have permanent visas. Your application will include the following: Cover page – includes abstract/project summary of up to 250 words NIH-formatted biosketch for PI and collaborators Funding level maximum is 60k , which would ideally include support for use of DRC/IDOM core facilities - (https://www.
med. upenn. edu/idom/drc/cores/index.
html) . Budget and Budget Justification – for one year; 1 page only. Equipment, travel, and PI salary are NOT permitted on budget.
Current Award period: April 1, 2026 - March 31, 2027. Specific aims, research strategy (significance, innovation, approach and preliminary studies) – up to 3 pages total Status of Institutional Review Board (IRB) approval for clinical studies or IACUC approval for animal use. If approvals are pending at the time of submission, they must be obtained before funding commences.
Funds will not be disbursed without copies of IRB / IACUC approval letters. If human subjects will be participating in the proposed research, an NIH Targeted / Planned Enrollment Table needs to be completed Submission is now electronic. Applications for a second year of funding should follow the format of new applications but also include a progress report describing accomplishments from Year 1 of funding - up to 4 pages total.
Evidence of progress from Year 1 of funding is essential. Please include an NIH Inclusion Enrollment Report if human subjects were involved in your research.
Once a grant is awarded, the responsibilities of successful applicants include involvement in the local diabetes community through seminar presentations and participation in local events of the diabetes research community, acknowledgement of Diabetes Center support in any publications emanating from the supported project, as well as progress reports and reporting of successful and independent grant applications resulting from the work supported by the DRC P&F grant.
Awardees are required to inform the DRC if the P&F Project receives external funding during the project period. Awarded funds MUST be used in the 12-month period of receipt of the award.
It is imperative that Pilot awardees are to cite the DRC DK019525 in all scientific posters, presentations and publications using the specific language listed below: All awardees are asked to acknowledge DRC support in all scientific posters, presentations and publications using the specific language listed below: Direct DRC Funding Support: "This research was supported by a pilot award from the DRC at the University of Pennsylvania from a grant sponsored by NIH DK019525."
Awardees may be invited to present a seminar at the weekly IDOM/DRC Seminar Series. All awardees must present a poster at the Annual Diabetes Spring Symposium. A final progress report is due one month after the close of the project period.
The one page report will contain a synopsis of scientific progress, a list of resulting collaborations, publications, and grants, and a description of the relationship of the project to Core usage. Awardees must report yearly for 5 years and every five years after on publications, grants, awards, patents and promotions on core utilization. Awardees must apply for DRC Membership prior to receiving Pilot funds ( https://www.
med. upenn. edu/idom/drc/drc_app.
html ) For additional information, please contact: e-mail: henryli@pennmedicine. upenn. edu Dr. Patrick Seale, Director e-mail: sealep@pennmedicine.
upenn. edu Dr. Doris Stoffers , Associate Director Pilot and Feasibility Grants Program e-mail: stoffers@pennmedicine. upenn.
edu Institute for Diabetes, Obesity and Metabolism Smilow Center for Translational Research 3400 Civic Center Boulevard, 12th Floor Phone: 215-898-0198 | Fax 215-898-5408
Key questions and narrative sections extracted from the solicitation.
Project summary (max 250 words)
NIH biosketch for PI and collaborators
Research strategy (max 3 pages)
IRB/IACUC approval documentation
According to the current listing, eligibility includes: Faculty members affiliated with the University of Pennsylvania or Children's Hospital of Philadelphia community are likely eligible. Specifics should be confirmed on the program's website. Confirm the full requirements in the official notice before applying.
Diabetes Research Center Pilot and Feasibility Grant Program is funded by Perelman School of Medicine at the University of Pennsylvania (DRC). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Pennsylvania. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The full ASPECT NOFO (DE-FOA-0003647) posted September 4, 2026, eleven days later than the Notice of Intent predicted. The real document splits $58 million across two topic areas with anticipated award counts of 0-7 and 0-3, a cost share that jumps from 20 percent to 50 percent mid-project, a mandatory five-page concept paper due October 9, and a university eligibility restriction that decides team structure before anyone writes a word.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleUSDA and HHS announced Harvest to Hallways on August 24, 2026: $50M in new cafeteria infrastructure funding on top of $20M in Equipment Assistance Grants, up to $25M more in Patrick Leahy Farm to School awards for FY2026, and $30M in HHS nutrition research. Each pot has a different applicant, a different route, and a different timeline. Here is how to position for all three before the notices post.
Read article